Hossam El Benawi: Loading Dose While Treating LVT Could Mitigate Stroke
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn:
”’Loading Dose’ while treating Left ventricular thrombus could mitigate one of its most serious complication ”stroke”.
While many studies have compared DOACs and VKAs for the treatment of left ventricular thrombus (LVT), there is limited data on whether initiating treatment with a loading dose of DOACs can help prevent embolization.”
Mayo Clinic Multi-Center LVT study about DOAC Loading dose:
All over our study, 10 embolism events (DOAC: 4, VKA: 6).
· 50% of events (5/10) occurred within the first 8 weeks after LVT diagnosis.
Group comparison:
-At 6 months: DOAC 4.3% vs. VKA 1.8% (p = 0.37). Figure A
-All follow up: DOAC 5.7% vs. VKA 5.4% (p = 1.0). Figure B
In a subgroup analysis of patients treated with DOAC, we compared those with and without DOAC loading doses to the VKA group during the first 6 months.
-SSE ( systemic embolic events) incidence: 0% (loaded DOAC) vs. 5.7% (non-loaded DOAC) vs. 1.8% (VKA), p = 0.26. Figure C
-Events: 0/18 (loaded DOAC) vs. 3/52 (non-loaded DOAC) vs. 2/112 (VKA).
Numerically fewer SSE events in DOAC loading group vs. non-loading and VKA, but not statistically significant, likely due to small sample size).
Since 50% of embolization events occurred within the first 8 weeks, predominantly in the non-loading group, these findings suggest that initiating a loading phase early in treatment may be a more appropriate—and more consistent with FDA labeling for acute thrombosis—strategy to reduce SSE in patients with LVT.
Mayo Clinic Multi Center LVT Study, Part 1
Study Link”
Read the full article here.
Article: Comparison of Direct Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi, A Retrospective Cohort Study
Authors: Hossam Elbenawi, Kirsten Lipps, Samuel Heller Jr., David A. Liedl, Raymond C. Shields, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, Waldemar E. Wysokinski, Robert D. McBane, Damon E. Houghton

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology
-
Jul 23, 2026, 13:41Colleen Grady: Why Normal Hemoglobin Does Not Exclude Iron Deficiency
-
Jul 23, 2026, 13:22Jacob Kelly: AHA Review Highlights Coffee’s Cardiovascular Benefits